The FDA rejected Capricor Therapeutics' deramiocel Friday, two days before the agency's Nov. 22 deadline. Deramiocel is a cell therapy for Duchenne muscular dystrophy, given by IV every three months. About 15,000 Americans have the disease. It's the second time the FDA has rejected the drug. The first was in July 2025. In a public statement, the FDA said its letters to Capricor identify "serious data integrity violations" in Capricor's main trial, HOPE-3, that "cannot be remediated post-hoc." This July, an FDA advisory panel voted 9-3 that the evidence didn't support the drug for Duchenne heart disease. Capricor then changed its application to treating arm weakness. Capricor shares fell more than 80% in after-hours trading. The company will hold a call with investors Monday at 8:30 a.m. ET.

The FDA Says the Trial Can't Be Trusted

This camp says the trial was run badly enough that its numbers can't support an approval.

The FDA says Capricor broke the rules of its own trial. FDA inspectors found "unauthorized post hoc changes to the statistical analysis plan." They also found "violations of study blinding procedures" and other protocol violations. The agency said those problems "compromise the reliability of the study data." "The underlying data cannot serve as a reliable foundation for a marketing approval determination," the FDA said. The FDA also sent Capricor a separate letter about the inspection findings, and Capricor can respond to it.

Agency reviewers say the trial missed its goals anyway. FDA reviewers found the arm-function result wasn't statistically significant under the analysis plan they used. The FDA's July briefing said HOPE-3 "did not meet its pre-specified primary and secondary efficacy endpoints." By the FDA's count, 41.5% of patients on the drug had allergic-type reactions, compared with 15.4% on placebo. FDA reviewers said that gap "raises the possibility that treatment assignment could be inferred." In other words, patients and doctors might have guessed who got the real drug.

STAT's Adam Feuerstein says the decision should have been easy. Feuerstein is a senior biotech writer at STAT. He said the decision "should have been an easy one for regulators to make." He wrote that both of Capricor's trials "failed to show deramiocel could stave off heart failure or preserve muscle function in their arms." He noted the drug is aimed at teens and young men who can no longer walk. "Deramiocel didn't help them either," he wrote.

Capricor and Its Trial Doctors Say the Drug Works

This camp says two trials met their main goals, and asking for another one would be unethical.

Capricor says both trials hit their main targets. "Deramiocel has been studied in two randomized, double-blind, placebo-controlled trials, HOPE-2 and HOPE-3, both of which met their primary endpoints," said CEO Linda Marbán. "We stand behind the rigor of our clinical program and the integrity of our data, and we believe the data support approval," she said. Under Capricor's analysis plan, HOPE-3 patients lost arm function 54% more slowly than patients on placebo. The Lancet published that result in July. Capricor has called the analysis plan the FDA relied on "an unsigned incomplete internal draft."

Capricor had disclosed one inspection finding. On Nov. 10, Capricor said a July FDA inspection had turned up one observation, and that it had responded. Capricor's Friday statement didn't mention the FDA's data-integrity findings. It said the FDA found the data don't establish "substantial evidence of effectiveness" and "cites certain other clinical deficiencies."

The trial's doctors say another study would be wrong. In late October, 28 doctors who ran HOPE-3 wrote to FDA leaders urging approval. Dr. Craig McDonald shared the letter. He's the trial's national lead investigator, at UC Davis Health. The doctors said keeping arm function lets patients "self-feed, bring a hand to the mouth, or operate a powered wheelchair or communication device." They said it would be "unethical" to run another trial. McDonald has called the 54% slowing "extraordinary in Duchenne."

Families Want Both Sides to Keep Working on Approval

This camp says families who gave years to these trials deserve a next step and answers on access.

Two patient groups say the decision hits trial families hard. Parent Project Muscular Dystrophy (PPMD), a Duchenne patient group, called the decision "devastating" and "heartbreaking news for the Duchenne community." It said families "sacrificed years of their time through trial participation." CureDuchenne, another Duchenne nonprofit, said the news was "deeply disappointing," especially for families in the HOPE-2 and HOPE-3 trials.

PPMD says the drug could still be approved. The group said the rejection "does not yet mark the end of the road." It said it will "partner with both Capricor and the FDA in order to support a path forward." CureDuchenne said it will work with Capricor on "possible next steps."

Patients already on the drug don't know what happens next. PPMD said it's still unclear whether current trial patients can keep getting deramiocel. It told families to contact their study teams.

Where This Lands

The FDA says Capricor broke its own trial rules and that no after-the-fact fix can rescue the data. Capricor says both of its trials met their goals and its data are sound. The doctors who ran the trial say another one would be unethical. Families want the two sides to keep working toward approval. Some patients don't know if they'll keep getting the drug. Capricor can now answer the FDA's letter on the inspection findings. The company says it will share next steps after it reviews the rejection letter. It has also started talks with regulators in Europe and Japan.

Sources